Heart, Stroke Care For Disadvantaged Minorities

Heart, Stroke Care For Disadvantaged Minorities
UCLA has been awarded a four-year, $3.89 million grant from the American Heart Association to establish a new research center focused on improving the health of disadvantaged minority patients at risk for stroke and heart attack. In addition to training future scientists, the center will collaborate with community partners on two studies exploring how to prevent stroke survivors from suffering a second stroke.

New Data On Highly Effective Treatment For Chronic Rhinosinusitis Presented By OptiNose

New Data On Highly Effective Treatment For Chronic Rhinosinusitis Presented By OptiNose
OptiNose has announced important new results from a Phase II trial of its novel nasal drug delivery device with fluticasone for the treatment of chronic rhinosinusitis. Patients in the active treatment group experienced significant improvements in nasal symptoms, nasal discomfort and sense of smell. There was also a highly significant and progressive reduction in nasal swelling.

GlobeImmune Initiates Phase 1 Clinical Trial With NCI In CEA - Metatastic Cancers

GlobeImmune Initiates Phase 1 Clinical Trial With NCI In CEA - Metatastic Cancers
GlobeImmune, Inc. announced the initiation of a Phase 1 clinical trial to investigate the safety and tolerability of a new Tarmogen, GI-6207, in patients with metastatic cancers that over-express carcinoembryonic antigen (CEA). This is the third new Tarmogen(R) product candidate to enter human clinical trials over the last four years. James L. Gulley, M.D., Ph.D., F.A.C.P.